Premium
Thiazolidinedione inhibits production of RANTES in a cytokine‐treated human lung epithelial cell line
Author(s) -
Momoi Atsuko,
Murao Koji,
Imachi Hitomi,
Sayo Yoshitaka,
Nakamura Hiroyuki,
Hosokawa Hitoshi,
Sato Makoto,
Fujita Jiro,
Okada Hiroki,
Ishida Toshihiko,
Takahara Jiro
Publication year - 1999
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(99)00678-x
Subject(s) - chemokine , cytokine , eosinophil , tumor necrosis factor alpha , a549 cell , interleukin 8 , lung , immunology , ccl5 , cancer research , medicine , t cell , inflammation , asthma , immune system , il 2 receptor
The chemokine RANTES is a potent chemoattractant for eosinophils. RANTES is produced by lung epithelial cells during eosinophil‐rich inflammatory diseases such as asthma. In this study, we examined the effects of thiazolidinediones (TZD) on RANTES expression in a human lung epithelial cell line, A549. In A549 cells, interleukin‐1β and tumor necrosis factor‐α induced endogenous RANTES protein secretion, mRNA expression, and promoter activity. The TZD inhibited these effects. Our data indicate that the suppression of the expression of RANTES can be accomplished by TZD treatment, raising the possibility that TZD might be of therapeutic value in diseases such as asthma.